News and Trends 5 Jul 2016
Spanish Biotech gets New Milestone in Biosimilar Race with Amgen
The Spanish Cinfa Biotech’s race to compete with Amgen’s blockbuster for Chemotherapy-induced Neutropenia continues: the Neulasta biosimilar passes Phase I trials. Neulasta (pegfilgrastim) is a slightly longer acting version of Amgen’s other blockbuster Neupogen (the template for the first ever US approved biosimilar – from Novartis), the combined sales of which account for over 30% of Amgen’s income. […]